Silence Therapeutics Plc (SLN.L) said it has signed an agreement with MiReven Pty Ltd. to assess the delivery potential of Silence Therapeutics' proprietary delivery systems with MiReven's novel microRNA-based therapeutics. MiReven, an Australian-based microRNA company, is commercialising discoveries from the Western Australian Institute for Medical Research on the anti-cancer potential of miR-7.
As per the terms of the agreement, Silence Therapeutics will formulate a miR-7 mimetic with its proprietary AtuPLEX, DACC and DBTC delivery systems in order to assess miR-7 in various cancer models. The company will undertake in vitro and in vivo studies of the formulated miR-7. Silence Therapeutics is being paid an undisclosed fee for the collaboration.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.